Viruses readily evolve, and SARS-CoV-2 is no exception. With the advent of several SARS-CoV-2 vaccines, scientists are concerned about the possibility of escape variants as new variants continue to emerge. These variants evade critical antibody residues required for binding and immune detection and may affect vaccine efficacy. In this webinar, scientists will discuss the emergence of SARS-CoV-2 variants and strategies for monitoring, tracking, and mitigating SARS-CoV-2 escape variants.

Topics to be covered

-How to build and sustain a SARS-CoV-2 variant sequencing core
-Overcoming SARS-CoV-2 variants by IgM antibodies

  • 1622135155-06f8ee240adabef9
    Dirk P. Dittmer, PhD
    Professor, Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, Program Leader Global Oncology, Program Leader Virology Director, UNC Vironomics Core University of North Carolina at Chapel Hill
    Dirk Dittmer is a professor of microbiology and immunology at the University of North Carolina at Chapel Hill. He is the director of the UNC Vironomic Core, which supports clinical trials in the United States and globally, and co-director of the UNC Lineberger Global Oncology Program, which addresses growing international disparities in cancer incidence and death. Dittmer earned his PhD in 1994 from Princeton University under the mentorship of Arnold Levine and was the first to describe gain of function hot spot mutations in p53. He completed his postdoctoral studies at Sandford University in virology investigating human cytomegalovirus and Kaposi sarcoma-associated herpesvirus (KSHV). Dittmer’s research group investigates cancers that develop in the context of immunodeficiency and HIV/AIDS. His team was the first to describe KSHV extracellular vehicles and viral miRNAs found at high levels in human plasma. Dittmer studies all fundamental interaction points between viruses and hosts. Since the emergence of the COVID-19 pandemic, Dittmer has been tracking and monitoring changes in the sequence of SARS-CoV-2 to identify mutations and track its history.
  • 1622135356-06bb4b0b5d796a72
    Zhiqiang Ku, PhD
    Postdoctoral Fellow, Laboratory of Zhiqiang An, PhD Texas Therapeutic Institute, University of Texas Health Science Center at Houston
    Zhiqiang Ku received his PhD at Institute Pasteur of Shanghai, Chinese Academy of Sciences. Subsequently, he worked as a scientist at the Boehringer-Ingelheim R&D Center in Shanghai. Ku joined Zhiqiang An’s lab in 2017 to work on antibody discovery. He used a phage displayed antibody library and discovered antibody candidates for about ten targets that are involved in cancers, metabolic diseases, and infectious diseases. Two antibodies discovered by Ku are now being developed with biotech partners. One antibody targets a myeloid checkpoint inhibitory receptor for the treatment of solid tumors and is now in the pre-IND stage. Another antibody targets SARS-CoV-2 for COVID-19 treatment and is now in the IND stage.